Shares of Exelixis EXEL were down 5.13% on Jan. 24, following a downgrade in rating by analysts at Oppenheimer. Oppenheimer ...

Fintel reports that on January 27, 2025, Morgan Stanley upgraded their outlook for Exelixis (NasdaqGS:EXEL) from Equal-Weight to Overweight. Analyst Price Forecast Suggests 4.10% Upside As of December ...

Stifel Nicolaus analyst Stephen Willey maintained a Hold rating on Exelixis (EXEL – Research Report) today and set a price target of $30.00.

Exelixis (EXEL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason Gerberry from ...

Park Avenue Securities LLC acquired a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and ...

On Friday, Exelixis Inc (EXEL) stock saw a decline, ending the day at $32.38 which represents a decrease of $-1.75 or -5.13% from the prior close of $34.13. The stock opened at $33.49 and touched a ...

Exelixis Inc (EXEL) stock saw a modest uptick, ending the day at $34.13 which represents a slight increase of $1.25 or 3.80% from the prior close of $32.88. The stock opened at $33 and touched a low ...

A research team from Columbia Engineering and the Irving Institute for Cancer Dynamics made a pivotal discovery in the field ...

Kassa and others said Big Pharma continues to invest even as private equity funds have pulled back. He noted ...

Riverwater Partners, an investment management company, released its “Sustainable Value Strategy” Q4 2024 investor letter. A copy of the letter can be downloaded here.

Exelixis (NASDAQ:EXEL – Get Free Report) had its price target raised by research analysts at Truist Financial from $38.00 to ...

Sarepta Therapeutics' Elevidys for DMD shows revenue potential, with market cap justified at $11.4bn and potential for >50% ...